Karyopharm Therapeutics (KPTI)

Add to Watchlists
Create an Alert
9.37 -0.07  -0.74% NASDAQ Apr 28, 22:00 Delayed 2m USD
View Full Chart
KPTI Price Chart
View All Performance Charts

KPTI Total Returns Comparison

Advertisement

One Page Reports

Profile

  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • URL: http://www.karyopharm.com
  • Investor Relations URL: http://investors.karyopharm.com/
  • HQ Country: United States
  • HQ State/Province: Massachusetts
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2016
  • Est. Current Fiscal Year End: December 31, 2016
  • Last Fiscal Quarter End: December 31, 2015
  • Last Fiscal Year End: December 31, 2015
  • Next Earnings Release: N/A
  • NAICS Name: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry Name: Pharmaceutical and Medicine Manufacturing
  • NAICS Sector Name: Manufacturing
  • Profile: Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

KPTI Comparables

Edit

KPTI Excel Add-In Codes

  • Name: =YCI("KPTI","name")
  • Description: =YCI("KPTI","description")
  • Sector: =YCI("KPTI","sector")
  • Industry: =YCI("KPTI","industry")
  • Est. Current Fiscal Year End: =YCI("KPTI","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.